2493 related articles for article (PubMed ID: 32176591)
1. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
2. Exosomes in the tumor microenvironment as mediators of cancer therapy resistance.
Li I; Nabet BY
Mol Cancer; 2019 Mar; 18(1):32. PubMed ID: 30823926
[TBL] [Abstract][Full Text] [Related]
3. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.
Khalaf K; Hana D; Chou JT; Singh C; Mackiewicz A; Kaczmarek M
Front Immunol; 2021; 12():656364. PubMed ID: 34122412
[TBL] [Abstract][Full Text] [Related]
4. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
Anari F; Ramamurthy C; Zibelman M
Future Oncol; 2018 Jun; 14(14):1409-1421. PubMed ID: 29848096
[TBL] [Abstract][Full Text] [Related]
5. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
[TBL] [Abstract][Full Text] [Related]
6. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA
Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143
[TBL] [Abstract][Full Text] [Related]
7. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971
[TBL] [Abstract][Full Text] [Related]
8. Seeking and Exploring Efficient Ways to Target Cancer.
Kallunki T
Cells; 2020 Sep; 9(9):. PubMed ID: 32957725
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
10. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
11. 3D printed
Chen H; Cheng Y; Wang X; Wang J; Shi X; Li X; Tan W; Tan Z
Theranostics; 2020; 10(26):12127-12143. PubMed ID: 33204333
[No Abstract] [Full Text] [Related]
12. Stromal cell-laden 3D hydrogel microwell arrays as tumor microenvironment model for studying stiffness dependent stromal cell-cancer interactions.
Yue X; Nguyen TD; Zellmer V; Zhang S; Zorlutuna P
Biomaterials; 2018 Jul; 170():37-48. PubMed ID: 29653286
[TBL] [Abstract][Full Text] [Related]
13. The Microenvironment of Lung Cancer and Therapeutic Implications.
Mittal V; El Rayes T; Narula N; McGraw TE; Altorki NK; Barcellos-Hoff MH
Adv Exp Med Biol; 2016; 890():75-110. PubMed ID: 26703800
[TBL] [Abstract][Full Text] [Related]
14. Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C; Mendes R; Baptista PV; Fernandes AR
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781344
[TBL] [Abstract][Full Text] [Related]
15. Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.
Darvishi B; Majidzadeh-A K; Ghadirian R; Mosayebzadeh M; Farahmand L
Life Sci; 2019 Jan; 217():34-40. PubMed ID: 30472294
[TBL] [Abstract][Full Text] [Related]
16. Tumor stroma as targets for cancer therapy.
Zhang J; Liu J
Pharmacol Ther; 2013 Feb; 137(2):200-15. PubMed ID: 23064233
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases.
Ceelen W; Ramsay RG; Narasimhan V; Heriot AG; De Wever O
Trends Cancer; 2020 Mar; 6(3):236-246. PubMed ID: 32101726
[TBL] [Abstract][Full Text] [Related]
19. The bad seed: Cancer stem cells in tumor development and resistance.
Koren E; Fuchs Y
Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
[TBL] [Abstract][Full Text] [Related]
20. 3D models in the new era of immune oncology: focus on T cells, CAF and ECM.
Di Modugno F; Colosi C; Trono P; Antonacci G; Ruocco G; Nisticò P
J Exp Clin Cancer Res; 2019 Mar; 38(1):117. PubMed ID: 30898166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
